Publication Name	World Journal of Gastroenterology
Manuscript ID	26283
Country	China

Received	2016-04-01 16:24
Peer-Review Started	2016-04-07 11:02
First Decision by Editorial Office Director
Return for Revision	2016-05-13 17:51
Revised	2016-05-24 18:23
Publication Fee Transferred
Second Decision by Editor	2016-06-08 18:27
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2016-06-15 18:22
Articles in Press	2016-06-15 18:22
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-12 17:27
Publish the Manuscript Online	2016-07-22 13:48

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy
Manuscript Source	Invited Manuscript
All Author List	Man Fai Law, Rita Ho, Carmen KM Cheung, Lydia HP Tam, Karen Ma, Kent CY So, Bonaventure Ip, Jacqueline So, Jennifer Lai, Joyce Ng and Tommy HC Tam
Funding Agency and Grant Number
Corresponding Author	Dr. Man Fai Law, Department of Medicine and Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China. mflaw99@yahoo.com.hk
Key Words	Hepatitis B virus reactivation; Hematological malignancies; Rituximab; Hematopoietic stem cell transplant; Prophylactic antiviral therapy
Core Tip	Hepatitis due to hepatitis B virus (HBV) reactivation can be severe and potentially fatal. All patients with hematological malignancies receiving anticancer therapy should be screened for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen. Patients found to be positive for HBsAg should be given prophylactic antiviral therapy. For patients with resolved HBV infection, either pre-emptive therapy guided by serial HBV DNA monitoring or prophylactic antiviral therapy, especially for patients receiving high-risk therapy are reasonable options. Further studies are needed to find out the best prophylactic strategy in the era of targeted therapy for hematological malignancies.
Publish Date	2016-07-22 13:48
Citation	Law MF, Ho R, Cheung CKM, Tam LHP, Ma K, So KCY, Ip B, So J, Lai J, Ng J, Tam THC. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol 2016; 22(28): 6484-6500
URL	http://www.wjgnet.com/1007-9327/full/v22/i28/6484.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i28.6484

Full Article (PDF)	WJG-22-6484.pdf
Full Article (Word)	WJG-22-6484.doc
Manuscript File	26283-Review.doc
Answering Reviewers	26283-Answering reviewers.pdf
Audio Core Tip	26283-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	26283-Conflict-of-interest statement.pdf
Copyright License Agreement	26283-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	26283-Language certificate.pdf
Peer-review Report	26283-Peer-review(s).pdf
Scientific Misconduct Check	26283-Scientific misconduct check.pdf
Scientific Editor Work List	26283-Scientific editor work list.pdf